|1.||Rundfeldt, Chris: 1 article (03/2007)|
|2.||Hoppmann, Joachim: 1 article (03/2007)|
|3.||Kietzmann, Manfred: 1 article (03/2007)|
|4.||Bäumer, Wolfgang: 1 article (03/2007)|
|5.||Hornix, M: 1 article (04/2003)|
|6.||Schalkwijk, J: 1 article (04/2003)|
|7.||de Jongh, G J: 1 article (04/2003)|
|8.||Kucharekova, M: 1 article (04/2003)|
|9.||van der Valk, P G M: 1 article (04/2003)|
|10.||Ashikaga, T: 1 article (04/2003)|
|1.||Atopic Dermatitis (Atopic Eczema)
08/01/2002 - "International, multicentre, prospective, randomized double-blind, left-right studies of cipamfylline vs. vehicle and cipamfylline vs. hydrocortisone 17-butyrate in adult patients with stable symmetrical atopic dermatitis on the arms. "
08/01/2002 - "Cipamfylline cream is significantly more effective than vehicle, but significantly less effective than hydrocortisone 17-butyrate cream in the treatment of atopic dermatitis."
08/01/2002 - "Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis."
03/01/2007 - "Results of early clinical trials with both topically (cipamfylline, CP80,633) and systemically (CC-10004) active PDE4 inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis. "
|2.||Psoriasis (Pustulosis Palmaris et Plantaris)
|4.||Contact Dermatitis (Eczema, Contact)
|1.||Phosphodiesterase 4 Inhibitors